Yoshitaka Ogata

Overexpression of PIAS3 Suppresses Cell Growth, Restores the Drug Sensitivity of Human Lung Cancer Cells in Association with PI3-K/Akt Inactivation

Yoshitaka Ogata, Tadashi Osaki, Tetsuji Naka et al. · Neoplasia · 2006 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Seigo Minami, Yoshitaka Ogata, Shouichi Ihara et al. · Lung Cancer Targets and Therapy · 2017 · 40 citations · Full text

Medicine, Oncology, Chemotherapy +15

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor

Seigo Minami, Yoshitaka Ogata, Shouichi Ihara et al. · World Journal of Oncology · 2017 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer

Takayuki Shiroyama, Takashi Kijima, Kiyoshi Komuta et al. · Cancer Chemotherapy and Pharmacology · 2012 · 22 citations

Medicine, Geriatric Medicine, Oncology +10

A Phase I/II Study Comparing Regimen Schedules of Gemcitabine and Docetaxel in Japanese Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Kaoru Matsui, Tomonori Hirashima, Takashi Nitta et al. · Japanese Journal of Clinical Oncology · 2005 · 21 citations

Medicine, Oncology, Pharmacology +13